323 related articles for article (PubMed ID: 19302584)
1. Unusual mid-shaft fractures during long-term bisphosphonate therapy.
Odvina CV; Levy S; Rao S; Zerwekh JE; Rao DS
Clin Endocrinol (Oxf); 2010 Feb; 72(2):161-8. PubMed ID: 19302584
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of alendronate and risedronate for postmenopausal osteoporosis.
Iwamoto J; Takeda T; Sato Y
Curr Med Res Opin; 2006 May; 22(5):919-28. PubMed ID: 16709313
[TBL] [Abstract][Full Text] [Related]
3. Aging bone and osteoporosis: strategies for preventing fractures in the elderly.
Ettinger MP
Arch Intern Med; 2003 Oct; 163(18):2237-46. PubMed ID: 14557222
[TBL] [Abstract][Full Text] [Related]
4. Bone turnover in bone biopsies of patients with low-energy cortical fractures receiving bisphosphonates: a case series.
Armamento-Villareal R; Napoli N; Diemer K; Watkins M; Civitelli R; Teitelbaum S; Novack D
Calcif Tissue Int; 2009 Jul; 85(1):37-44. PubMed ID: 19548019
[TBL] [Abstract][Full Text] [Related]
5. [New development in bisphosphonate treatment. When and how long should patients take bisphosphonates for osteoporosis?].
Yamaguchi T; Sugimoto T
Clin Calcium; 2009 Jan; 19(1):38-43. PubMed ID: 19122263
[TBL] [Abstract][Full Text] [Related]
6. What is the optimal duration of bisphosphonate therapy?
Ott SM
Cleve Clin J Med; 2011 Sep; 78(9):619-30. PubMed ID: 21885695
[TBL] [Abstract][Full Text] [Related]
7. Unusual subtrochanteric femoral insufficiency fractures associated with the prolonged use of alendronate and risedronate: a report of two cases.
Angthong C; Angthong W
J Med Assoc Thai; 2011 Dec; 94 Suppl 7():S214-20. PubMed ID: 22619933
[TBL] [Abstract][Full Text] [Related]
8. Bisphosphonates and low-impact femoral fractures: current evidence on alendronate-fracture risk.
Schneider JP
Geriatrics; 2009 Jan; 64(1):18-23. PubMed ID: 19256578
[TBL] [Abstract][Full Text] [Related]
9. Pelvic fractures associated with long-term bisphosphonate therapy - case report.
Patel V; Graves L; Lukert B
J Musculoskelet Neuronal Interact; 2013 Jun; 13(2):251-4. PubMed ID: 23728112
[TBL] [Abstract][Full Text] [Related]
10. Clinical investigation of C-terminal cross-linking telopeptide test in prevention and management of bisphosphonate-associated osteonecrosis of the jaws.
Kunchur R; Need A; Hughes T; Goss A
J Oral Maxillofac Surg; 2009 Jun; 67(6):1167-73. PubMed ID: 19446200
[TBL] [Abstract][Full Text] [Related]
11. Biomechanical effects of teriparatide in women with osteoporosis treated previously with alendronate and risedronate: results from quantitative computed tomography-based finite element analysis of the vertebral body.
Chevalier Y; Quek E; Borah B; Gross G; Stewart J; Lang T; Zysset P
Bone; 2010 Jan; 46(1):41-8. PubMed ID: 19800436
[TBL] [Abstract][Full Text] [Related]
12. Drug injury in the upper gastrointestinal tract: effects of alendronate.
Khapra AP; Rose S
Gastrointest Endosc Clin N Am; 2006 Jan; 16(1):99-110. PubMed ID: 16546026
[TBL] [Abstract][Full Text] [Related]
13. Atraumatic bilateral femur fracture in long-term bisphosphonate use.
Goddard MS; Reid KR; Johnston JC; Khanuja HS
Orthopedics; 2009 Aug; 32(8):. PubMed ID: 19708622
[TBL] [Abstract][Full Text] [Related]
14. [New development in bisphosphonate treatment. Review of effect on bone metabolism by minodronic acid in primary osteoporosis].
Fukunaga M
Clin Calcium; 2009 Jan; 19(1):63-73. PubMed ID: 19122266
[TBL] [Abstract][Full Text] [Related]
15. A review of the literature on osteonecrosis of the jaw in patients with osteoporosis treated with oral bisphosphonates: prevalence, risk factors, and clinical characteristics.
Pazianas M; Miller P; Blumentals WA; Bernal M; Kothawala P
Clin Ther; 2007 Aug; 29(8):1548-58. PubMed ID: 17919538
[TBL] [Abstract][Full Text] [Related]
16. Prevalence of evaluation and treatment of glucocorticoid-induced osteoporosis in men.
Cruse LM; Valeriano J; Vasey FB; Carter JD
J Clin Rheumatol; 2006 Oct; 12(5):221-5. PubMed ID: 17023807
[TBL] [Abstract][Full Text] [Related]
17. Prolonged bisphosphonate release after treatment in women with osteoporosis. Relationship with bone turnover.
Peris P; Torra M; Olivares V; Reyes R; Monegal A; Martínez-Ferrer A; Guañabens N
Bone; 2011 Oct; 49(4):706-9. PubMed ID: 21742070
[TBL] [Abstract][Full Text] [Related]
18. Determinants of persistence with bisphosphonates: a study in women with postmenopausal osteoporosis.
Penning-van Beest FJ; Goettsch WG; Erkens JA; Herings RM
Clin Ther; 2006 Feb; 28(2):236-42. PubMed ID: 16678644
[TBL] [Abstract][Full Text] [Related]
19. Corticosteroids: no drug prevention of fractures needed.
Prescrire Int; 2009 Aug; 18(102):175. PubMed ID: 19746563
[TBL] [Abstract][Full Text] [Related]
20. [When should bisphosphonate treatment be discontinued?].
Eriksen EF; Halse J
Tidsskr Nor Laegeforen; 2012 Aug; 132(14):1630-2. PubMed ID: 22875131
[No Abstract] [Full Text] [Related]
[Next] [New Search]
